Downloads

Scientific Posters - Cancer Research

2023

  • Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer presented at the AACR Annual Meeting
  • Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action presented at the AACR Annual Meeting

2022

  • PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer presented at the AACR Annual Meeting in collaboration with Bayer AG and Aurexel Life Sciences Ltd
  • Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model presented at the AACR Annual Meeting in collaboration with Bayer AG
  • Orthotopic model of Hepatocellular Carcinoma (HCC) using Huh-7 and HepG2 cells, application of micro-CT in detection of cancer progression presented at the AACR Annual Meeting in collaboration with Bayer AS
  • Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro presented at the AACR Annual Meeting

2021

  • Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model presented at the AACR Annual Meeting in collaboration with Bayer AG
  • Novel Preclinical Orthotopic and Bone Metastasis TNBC models for assessment of immunotherapy and chemotherapy responses presented at the AACR Annual Meeting in collaboration with Taconic Biosciences
  • Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model presented at the ASCO Genitourinary Cancers Symposium in collaboration with Aurexel Life Sciences Ltd. and Bayer AG

2020

  • A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice presented at SITC Annual Meeting by Mari Suominen
  • Differential Effects of Two Immunomodulators, Chemotherapy and Bone targeting Agent on Cancer Progression in a Syngeneic Bone Metastasis Model of Triple Negative Breast Cancer presented at Advances of Immuno-Oncology Congress by Mari Suominen
  • T Cell Killing Assay for Analyzing the Effects of Immunotherapies In Vitro presented at Advances in Immuno-Oncology Congress by Jenni Mäki-Jouppila
  • Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer presented at AACR Annual Meeting by Mari Suominen
  • Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro presented at AACR Annual Meeting by Jenni Mäki-Jouppila
  • Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line presented at AACR Annual Meeting by Justyna Zdrojewska
  • Efficacy of Pembrolizumab and Assessment of Tumor-Infiltrating Immune Cells in Preclinical Models of Primary and Bone Metastatic Triple-Negative Breast Cancer at Tumor Models San Francisco meeting by Mari Suominen
  • Characterization of Anti-CTLA-4 Effects on Tumor Growth and Immune Microenvironment in a Syngeneic CT26.WT Colon Carcinoma Mouse Model at Tumor Models San Francisco meeting by Justyna Zdrojewska

2019

  • Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice in collaboration with Univeristy Central Animal Laboratory (University of Turku) and Taconic BioSciences presented at the SITC 2019 Meeting
  • Lack of immunotherapy efficacy in a syngeneic bone metastasis model of triple-negative breast cancer presented at the AACR-NCI-EORTC Meeting 
  • Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab in collaboration with Taconic Biosciences presented at the AACR-NCI-EORTC Meeting
  • Establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice and validation of pembrolizumab efficacy in collaboration with Taconic Biosciences presented at the AACR-NCI-EORTC Meeting 
  • Validation of a preclinical model for bone metastatic triple negative breast cancer in collaboration with Polyphor Ltd presented at the AACR Annual Meeting
  • In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology presented at the AACR Annual Meeting
  • Systemic and local syngeneic bone metastasis models for immuno-oncology drug development in collaboration with Bayer AG presented at the AACR Annual Meeting
  • Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model in collaboration with OracleBio and BioSiteHisto presented at the AACR Annual Meeting
  • Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies in collaboration with Bayer AS presented at the AACR Annual Meeting
  • Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development in collaboration with Pharmaxis presented at the AACR Annual Meeting
  • The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer presented at the AACR Annual Meeting

2018

  • Systemic and local syngeneic bone metastasis models for immuno-oncology drug development in collaboration with Bayer AG presented at the EORTC-NCI-AACR Symposium
  • Characterization of tumor-infiltrating immune cells and the efficacy of pembrolizumab in preclinical models of primary and bone metastatic triple-negative breast cancer in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the EORTC-NCI-AACR Symposium
  • Prostate Cancer Bone Metastasis Model for Preclinical Evaluation of Radiotherapeutics presented at EANM’ 18 Congress (E-poster walk)
  • Characterization of pre-clinical models of luminal B breast cancer in orthotopicand bone metastatic settings in collaboration with BioSiteHisto Ltd presented at the 15th European Pathology Congress 2018

  • Characterization of Tumor Growth Supported by Novel Dihydrotestosterone Releasing Implants in a Subcutaneous Prostate Cancer Xenograft Model in collaboration with PreclinApps Ltd presented at the Scand-LAS 2018 Annual Meeting

  • PD-1/PD-L1 Expression and Tumor-Infiltrating Immune Cells in Triple-Negative Breast Cancer: Characterization of Preclinical Primary Tumor and Bone Metastasis Models in Humanized Mice in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the AACR Annual Meeting
  • Hormone Receptor and HER2/HER3 Expression in Preclinical Breast Cancer Models of Primary Tumor and Bone Metastasis in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the AACR Annual Meeting
  • Drug Sensitivity Profiling of BT-474 Breast Cancer Cell Line for Identification of Novel Therapies Targeting HER2-positive Breast Cancer in collaboration with Institute for Molecular Medicine Finland FIMM presented at the AACR Annual Meeting
  • Phenotypic Screening Using AMIDA Identifies Different Drug Responses in Breast and Prostate Cancer Cell Lines in an Organotypic Cell Culture Model in collaboration with University of Turku presented at the AACR Annual Meeting
  • Differential Efficacy of PD-1 Targeted Immunomodulation in Preclinical Models of Primary and Bone Metastatic Triple-Negative Breast Cancer in collaboration with BioSiteHisto Ltd and Taconic Biosciences presented at the AACR Annual Meeting
  • Castration-Resistant Prostate Cancer Bone Metastasis Model to Assess New Therapeutics in collaboration with Bayer AG presented at the AACR Annual Meeting
  • Anti-PD-1 Therapy Reduces Bone Lesion Growth in a Novel Syngeneic Bladder Cancer Bone Metastasis Model in collaboration with Bayer AG presented at the AACR Annual Meeting
  • Humanized Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immuno-Oncology Therapies in collaboration with BioSiteHisto Ltd and Taconic Biosciences presented at the ITOC5 Conference

2017

  • Bone phenotype of human immune system engrafted mice in collaboration with Taconic Biosciences at the ASBMR Annual Meeting
  • Effects of estrogen removal by ovariectomy on growth of human MCF-7 breast cancer cells in bone at the ASBMR Annual Meeting
  • Active human immune system induces more severe osteoblastic bone reaction in a humanized mouse model of breast cancer bone metastasis in collaboration with Taconic Biosciences at ASBMR Annual Meeting (oral presentation)
  • Preclinical efficacy model to promote immunotherapy development for prostate cancer at AACR Annual Meeting
  • New preclinical model for immuno-oncology: Combination of tumor, bone microenvironment and immune system in collaboration with Taconic Biosciences at AACR Annual Meeting
  • Immunodeficient mice differentially sensitize to estrogen and exhibit severe estrogen-related adverse effects in orthotopic breast cancer model in collaboration with Taconic Biosciences at AACR Annual Meeting
  • Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model in collaboration with Institute for Molecular Medicine Finland FIMM at AACR Annual Meeting
  • Selective drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines in collaboration with Institute for Molecular Medicine Finland FIMM at AACR Annual Meeting
  • Importance of Tumor Microenvironment in the Preclinical Estrogen Receptor Positive Breast Cancer –Primary Tumor and Bone Metastasis Models with Orion Corporation Orion Pharma at AACR Annual Meeting (Oral Presentation)
  • Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model with Bayer Healthcare at AACR Annual Meeting
  • Estrogen induces severe urinary tract defects –a strain dependent difference in nude vs NOG female mice with Taconic Biosciences at Scand-LAS (oral presentation)

2016

  • Differential drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines with Fimm at EORTC-NCI-AACR Meeting
  • Effects of cabozantinib alone and in combination with bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis at ASBMR Annual Meeting
  • New models of breast and lung cancer bone metastases for preclinical efficacy testing with Bayer Healthcare at AACR Annual Meeting
  • PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastastatic prostate cancer model in mice with Bayer Healthcare at AACR Annual Meeting
  • Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis at AACR Annual Meeting
  • Utilizing a novel luciferase labeling technique to establish and validate preclinical models of pancreatic cancer at AACR Annual Meeting
  • Effects of cabozantinib alone and in combination with bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis Inc. and PreclinApps Ltd. at ASBMR Annual Meeting

2015

  • Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models with Bayer Healthcare at AACR Annual Meeting
  • Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis at AACR Annual Meeting (multiple myeloma)
  • Novel luciferase labeling technique to improve imaging of orthotopic pancreatic cancer model at AACR Annual Meeting
  • Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis at Hanson Wade Tumor Models Boston

2014

  • Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis with Bayer Healthcare at EORTC-NCI-AACR Symposium 2014 (radiotherapeutics and metastasis)
  • Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases with Bayer Healthcare at AACR Annual Meeting (radiotherapeutics and bone metastasis)
  • A new spectrum-selective cathepsininhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model with Virobay at AACR Annual Meeting 
  • Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model with Exelixis at AACR Annual Meeting
  • Culturing Cancer Cells on Myoma Tissue: Development of a Novel Fully Human Organotypic 3D Invasion Model Applicable as a Preclinical Tool for Cancer Drug Development with University of Oulu and Oulu University Hospital at World Pharma Congress
  • Development and validation of clinically predictive models for anti-cancer drug development at International Conference on Drug Discovery and Therapy

2013

  • Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis with Bayer HealthCare at CIBD Annual Meeting
  • A new spectrum-selective cathepsin inhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model with Virobay at CIBD Annual Meeting
  • Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis with Bayer HealthCare at AACR Annual Meeting
  • Inhibiting androgen receptor-associated Src signaling with VAL201 inhibits breast cancer growth in an orthotopic xenograft model with Valirx at AACR Annual Meeting
  • Inhibiting androgen receptor-associated Src signaling by VAL201 inhibits prostate cancer metastasis in an orthotopic mouse model with Valirx at AACR Annual Meeting
  • Improved imaging of orthotopic BxPC3 pancreatic adenocarcinoma xenograft using animal PET/CT at AACR Annual Meeting
  • Culturing Cancer Cells on Myoma Tissue: Development of a Novel Fully Human Organotypic 3D Invasion Model Applicable as a Preclinical Tool for Cancer Drug Development at AACR Annual Meeting

2012

  • Radium-223 Chloride Completely Prevents Tumor Growth in Bone and Increases Survival in a Mouse Model of Breast Cancer Bone Metastases in Preventive and Micro-metastatic Settings with Bayer HealthCare at AACR Annual Meeting
  • A Novel Organotypic 3D Invasion Platform to Advance Anti-Cancer Drug Development with University of Oulu (Institute of Dentistry)

2011

  • Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo with Bayer HealthCare at AACR Annual Meeting
  • Cabozantinib (XL184), a Dual MET-VEGFR2 Inhibitor, Blocks Osteoblastic and Osteolytic Progression of Human Prostate Cancer Xenograft Tumors in Mouse Bone with Exelixis at EORTC Annual Meeting
  • Validation of In Vitro Assays for Identifying Compounds That Affect Breast and Prostate Cancer Cells at ASBMR Annual Meeting 

2010

  • Diverging effects of doxorubicin, paclitaxel and cyclophosphamide on 4T1 mouse breast cancer primary tumor and metastases at Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference

2008

  • Quantitative image analysis method for measuring whole-body tumor burden in a mouse model of breast cancer bone metastasis at ASBMR Annual Meeting

2007

  • Heparin-like Polysaccharides Markedly Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis with BioTie Therapies and University of Virginia at ASBMR Annual Meeting